Where capital goes, what it unlocks, and what it does not.
This is a decision instrument, not a pitch animation. Capital is finite: every allocation here creates a real trade-off, exposes a real constraint, and produces an outcome that can be wrong. Nothing on this page is a projection, promise or guarantee.
One ecosystem, four verticals, one shared biological platform.
RobGenes is not ten companies. It is one biological data platform expressed through ten products, which is why capital deployed in one place raises the value of the others.
Genomic intelligence, longitudinal programs and epigenetic follow-up.
Pharmacogenomic intelligence and genetics-driven supplementation.
Training the professionals who deploy the ecosystem.
High-frequency consumer products powered by biological personalisation.
- —Three products generate revenue today. The rest require capital, time and regulatory clearance before they earn anything.
- —Enterprise and government contracts have long cycles. They are funded by consumer revenue, not the other way round.
- —Physical products are constrained by manufacturing and working capital, not by demand.
- —Under-funding a vertical does not delay it proportionally — below a threshold it simply does not ship.
- —Spreading capital across all ten products at once is the fastest way to under-deliver on all ten.
All outputs are illustrative modelling based on stated assumptions and are not projections, forecasts, guarantees or investment recommendations. Market size figures are third-party industry estimates that vary by source and definition. Products described as planned or in development do not yet generate revenue. Actual outcomes may be materially different, including total loss of capital. Regulatory status differs by jurisdiction and no statement here should be read as a medical or diagnostic claim.